Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease
Nagy A. Youssef(Duke University), Ayako Suzuki(Duke Medical Center), Martin Binks(Behavioral Health Services), Anna Mae Diehl(Duke Medical Center), Cynthia D. Guy(Duke University Health System), Manal F. Abdelmalek(Mayo Clinic), Alastair D. Smith(Duke Medical Center), Alessia Omenetti(Duke Medical Center)
Cited by 179
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sex and gender: modifiers of health, disease, and medicine
|The Lancet|2020|2k